Repository logo
 
Publication

Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients

2018-06Journal article Open access
Simple item page
dc.contributor.authorVeloso Gomes, F
dc.contributor.authorOliveira, J
dc.contributor.authorTomé Correia, M
dc.contributor.authorCosta, NV
dc.contributor.authorAbrantes, J
dc.contributor.authorTorres, D
dc.contributor.authorPereira, P
dc.contributor.authorFerreira, AI
dc.contributor.authorLuz, JH
dc.contributor.authorSpaepen, E
dc.contributor.authorBilhim, T
dc.contributor.authorCoimbra, E
dc.date.accessioned2021-11-22T15:50:05Z
dc.date.available2021-11-22T15:50:05Z
dc.date.issued2018-06
dc.description.abstractPurpose: To evaluate the efficacy and safety of transarterial chemoembolization with polyethylene glycol (PEG) drug-eluting embolic agents in the treatment of hepatocellular carcinoma (HCC). Materials and methods: A single-center retrospective study of 302 patients (258 men; 85.4%) with HCC treated during a 20-month period was conducted. The mean patient age was 66 years ± 10; 142 (47%) had Barcelona Clinic Liver Cancer stage A disease and 134 had (44.4%) stage B disease; 174 (57.6%) had a single HCC tumor, 65 (21.5%) had 2, and 62 (20.9%) had 3 or more. Mean index tumor size was 36.6 mm ± 24.8. One-month follow-up computed tomography (CT) response per modified Response Evaluation Criteria In Solid Tumors and clinical and biochemical safety were analyzed. Progression-free and overall survival were calculated by Kaplan-Meier method. Results: Median follow-up time was 11.9 months (95% confidence interval, 11.0-13.0 mo). One-month follow-up CT revealed complete response in 179 patients (63.2%), partial response in 63 (22.3%), stable disease in 16 (5.7%), and progressive disease in 25 (8.8%). The most frequent complications were postembolization syndrome in 18 patients (6%), liver abscess in 5 (1.7%), and puncture-site hematoma in 3 (1%). Biochemical toxicities occurred in 57 patients (11.6%). Survival analysis at 12 months showed a progression-free survival rate of 65.9% and overall survival rate of 93.5%. Patients who received transplants showed a 57.7% rate of complete pathologic response. Conclusions: Chemoembolization with PEG embolic agents for HCC is safe and effective, achieving an objective response rate of 85.5%.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Vasc Interv Radiol. 2018 Jun;29(6):841-849.pt_PT
dc.identifier.doi10.1016/j.jvir.2018.02.004.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3914
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectHCC URIpt_PT
dc.subjectAgedpt_PT
dc.subjectCarcinoma, Hepatocellular / therapy*pt_PT
dc.subjectFemalept_PT
dc.subjectMalept_PT
dc.subjectHumanspt_PT
dc.subjectChemoembolization, Therapeutic / methods*pt_PT
dc.subjectContrast Mediapt_PT
dc.subjectDisease Progressionpt_PT
dc.subjectLiver Neoplasms / therapy*pt_PT
dc.subjectPolyethylene Glycols / administration & dosage*pt_PT
dc.subjectSurvival Ratept_PT
dc.subjectRadiography, Interventionalpt_PT
dc.subjectRetrospective Studiespt_PT
dc.subjectTomography, X-Ray Computedpt_PT
dc.subjectTreatment Outcomept_PT
dc.titleChemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patientspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage849pt_PT
oaire.citation.startPage841pt_PT
oaire.citation.titleJournal of Vascular and Interventional Radiologypt_PT
oaire.citation.volume29pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JVIR 2018 841.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Download

Collections

URI - Artigos